A selective Innate Repair Receptor agonist investigated for neuroprotection and small fiber neuropathy
Tirzepatide liver-fat and body-composition MRI substudy SURPASS-3, relative liver-fat reduction -29.8/-39.6/-47.1% at 5/10/15 mg vs insulin degludec -11.2%: Gastaldelli Lancet D&E 2022
The form documents that a patient understands the treatment, acknowledges potential side effects (including serious adverse reactions like anaphylactic shock), and consents voluntarily to proceed
the increase of sphingomyelins pathway products in GWS, and decrease in ME/CFS (Naviaux et al., 2016, 2019), may therefore contribute to the muscle fatigue experienced by patients with these conditions
5775, pubmed.ncbi.nlm.nih.gov/1574445/, Morris, Gerwyn, et al